Register

Register

Register here to subscribe to the print and digital copies of PRIME Journal and get unrestricted access to all news, analysis and peer-reviewed content on our website.

Register or Find out more

Menu

PRIME Journal

Search Account

Already Registered?

Forgotten Password?

Register for free

Register for FREE and get unrestricted access to all news, analysis and peer-reviewed content, and create your own tailored alerts.

Register

Press Release

, ,

Lilly’s Taltz® (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis

Lilly’s Taltz® (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment…

Analysis

Opinion